Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology

Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology

nancy

nancy

Pharmacokinetics - Absorption: Nursing pharmacology
Medication administration - Safety principles: Nursing pharmacology
Pharmacokinetics - Elimination: Nursing pharmacology
Pharmacokinetics - Distribution: Nursing pharmacology
Pharmacokinetics - Metabolism: Nursing pharmacology
Care of a client identifying as LGBTQ+: Nursing
Health and illness models: Nursing
Core measures: Nursing
Public health nursing: Nursing
Healthcare costs: Nursing
Health promotion and illness prevention: Nursing
Antacids: Nursing pharmacology
Antidiarrheals: Nursing pharmacology
Antiemetics: Nursing pharmacology
Antispasmodics (GI): Nursing pharmacology
Gallstone-dissolving agents: Nursing pharmacology
Gastric mucosal protective agents: Nursing pharmacology
Histamine H2 antagonists: Nursing pharmacology
Laxatives: Nursing pharmacology
Medications for hepatic encephalopathy: Nursing pharmacology
Pancreatic enzyme replacements: Nursing pharmacology
Proton pump inhibitors (PPIs): Nursing pharmacology
Treatment for Helicobacter pylori: Nursing pharmacology
Weight loss medications: Nursing pharmacology
Physiology of pain: Nursing
Pain
Vital signs - Pain: Nursing skills
Alpha-1 adrenergic blockers: Nursing pharmacology
Alpha-2 adrenergic agonists: Nursing pharmacology
Angiotensin II receptor blockers (ARBs): Nursing pharmacology
Angiotensin-converting enzyme (ACE) inhibitors: Nursing pharmacology
Antiarrhythmics: Nursing pharmacology
Anticoagulants - Direct thrombin and factor Xa inhibitors: Nursing pharmacology
Anticoagulants - Heparin: Nursing pharmacology
Anticoagulants - Warfarin: Nursing pharmacology
Antihyperlipidemics - Bile acid sequestrants and cholesterol absorption inhibitors: Nursing pharmacology
Antihyperlipidemics - Fibrates: Nursing pharmacology
Antihyperlipidemics - Miscellaneous: Nursing pharmacology
Antihyperlipidemics - Statins: Nursing pharmacology
Antiplatelet agents: Nursing pharmacology
Beta-adrenergic blockers: Nursing pharmacology
Calcium-channel blockers: Nursing pharmacology
Cardiac glycosides: Nursing pharmacology
Cholinergic therapy - Overview: Nursing pharmacology
Direct-acting vasodilators: Nursing pharmacology
Diuretics - Osmotic and carbonic anhydrase inhibitors: Nursing pharmacology
Diuretics - Thiazide, thiazide-like, loop, and potassium-sparing diuretics: Nursing pharmacology
Nitrates: Nursing pharmacology
Sympathomimetic medications: Nursing pharmacology
Amblyopia: Nursing
Cataracts: Nursing
Detached retina: Nursing
Hearing impairment and otosclerosis: Nursing
Legal blindness: Nursing
Macular degeneration: Nursing
Meniere disease: Nursing
Pharyngitis: Nursing
Retinoblastoma: Nursing
Strabismus: Nursing
Evidence-based practice (EBP): Nursing
Antiglaucoma medications: Nursing pharmacology
Acne: Nursing
Medications for acne vulgaris: Nursing pharmacology
Insulin: Nursing pharmacology
Oral antidiabetic medications - Alpha-glucosidase inhibitors: Nursing pharmacology
Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology
Oral antidiabetic medications - Sulfonylureas and meglitinides: Nursing pharmacology
Oral antidiabetic medications - Sodium-glucose co-transporter-2 (SGLT-2) inhibitors: Nursing pharmacology
Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics: Nursing pharmacology
Oral antidiabetic medications - Biguanides and thiazolidinediones: Nursing pharmacology
Antipsychotics: Nursing pharmacology
Grief and loss: Nursing
Stress and coping: Nursing

Notes

DPP4 INHIBITORS
DRUG NAME
sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina, Vipidia)
(Suffix: -gliptin)

CLASS
DPP4 inhibitors
MECHANISM OF ACTION
Increase the level of incretin hormones → increase insulin secretion, decrease glucagon secretion → reduce glucose production by the liver
INDICATIONS
Type 2 diabetes mellitus
ROUTE(S) OF ADMINISTRATION
PO
SIDE EFFECTS
  • Headaches
  • Nausea, vomiting, diarrhea, constipation
  • Mild urinary and respiratory infections
  • Hypoglycemia
  • Pancreatitis
  • Acute renal failure
  • Anaphylaxis
  • Angioedema
  • Stevens-Johnson syndrome
CONTRAINDICATIONS AND CAUTIONS
  • Pancreatitis
  • Hypoglycemia
  • Angioedema
  • Diabetic ketoacidosis (DKA)
  • Pregnancy and breastfeeding
  • Elderly clients
  • Other endocrine disorders
  • Hepatic or renal disorders
NURSING CONSIDERATIONS: DPP4 INHIBITORS
ASSESSMENT AND MONITORING
Assess
  • Laboratory test results: blood glucose, hemoglobin A1c, renal and hepatic function

Monitor
  • Hemoglobin A1c, blood glucose levels, and renal function tests; side effects

Evaluate
  • Therapeutic response: improved glucose control
CLIENT EDUCATION
  • Purpose of medication: lower blood glucose level
  • Take medication once daily, with or without food
  • Continue antidiabetic regimen: low-carbohydrate and high-fiber diet, regular physical activity, frequent blood glucose monitoring
  • Review the symptoms of hyperglycemia: fatigue, blurred vision, increased thirst, appetite, and urination
    • Check blood glucose level
    • Contact healthcare provider immediately
  • Review symptoms of hypoglycemia: hunger, headache, fatigue, tremors, dizziness, confusion
    • Check blood glucose level
    • Take about a half cup fruit juice, three glucose tablets, or approximately 15 grams of glucose or table sugar
    • Check blood sugar again after 15 minutes
  • Recognize serious side effects
    • Pancreatitis: severe abdominal or back pain
    • Renal failure: changes in urine produced, weight gain, swelling, blood in the urine
    • Stevens-Johnson syndrome: severe joint pain, blistered, peeling skin
Author: Maria Emfietzoglou, MD
Author: Katherine May, RN, BSN
Illustrator: Robyn Hughes, MScBMC

Transcript

Watch video only

Dipeptidyl peptidase-4 inhibitors, or DPP4 inhibitors for short, are medications used to treat type 2 diabetes mellitus. Type 2 diabetes mellitus is characterized by insulin resistance, which is when tissue cells have trouble responding to insulin in order to use glucose from the blood.

As a result, tissue cells starve for energy despite having high blood glucose levels, which is called hyperglycemia. Now, commonly used DPP4 inhibitors are sitagliptin, saxagliptin, linagliptin, and alogliptin. All of them end with the suffix -gliptin, which makes them easy to recognize!

DPP4 inhibitors are taken orally. Once administered, these medications inhibit the enzyme DPP4, which normally destroys the hormone incretin.

As a result, DPP4 inhibitors increase the levels of incretin, which in turn increases insulin secretion and decreases glucagon secretion. The end result is a reduction in glucose production by the liver, and thus a reduction in blood glucose levels.

Now, the most common side effects of DPP4 inhibitors include headaches, nausea, vomiting, and diarrhea or constipation, as well as mild infections of the upper respiratory or urinary tract.

In addition, they can increase the risk of hypoglycemia, pancreatitis, and acute renal failure. Less frequently, DPP4 inhibitors can cause life-threatening side effects, such as anaphylaxis, angioedema or Stevens Johnson syndrome.

As far as contraindications go, DPP4 inhibitors should not be used in clients with a history of pancreatitis, hypoglycemia, and angioedema.

They should also be avoided in clients with a history of diabetic ketoacidosis, or DKA for short, which is an acute life-threatening complication of diabetes.

Finally, precautions should be taken during pregnancy and breastfeeding, as well as in elderly clients, and those with other endocrine, hepatic, or renal disorders.

Now, if a client with type 2 diabetes is prescribed a DPP4 inhibitor like sitagliptin, be sure to review their most recent laboratory test results, including blood glucose, hemoglobin A1c, as well as their renal and hepatic function.

Next, explain how the medication works to lower their blood glucose level. Be sure to remind them that the medication is most effective when combined with an antidiabetic regimen, which includes following a low-carbohydrate and high-fiber diet, regular physical activity, and frequent blood glucose monitoring.

Sources

  1. "Focus on Nursing Pharmacology" LWW (2019)
  2. "Pharmacology: A patient-centered nursing process approach" Elsevier Health Sciences (2014)
  3. "Mosby's 2021 Nursing Drug Reference" Mosby (2021)
  4. "Saunders Comprehensive Review for the NCLEX-RN Examination" Saunders (2020)
  5. "Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13e)" McGraw-Hill Education (2018)
  6. "Lehne's Pharmacology for Nursing Care" Saunders (2019)